Mercedes Borge

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2996639/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	lbrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages. Haematologica, 2015, 100, e140-e142.	3.5	61
2	Neutrophils from chronic lymphocytic leukemia patients exhibit an increased capacity to release extracellular traps (NETs). Cancer Immunology, Immunotherapy, 2017, 66, 77-89.	4.2	48
3	Nurse-like cells control the activity of chronic lymphocytic leukemia B cells via galectin-1. Leukemia, 2013, 27, 1413-1416.	7.2	47
4	Effect of the BTK inhibitor ibrutinib on macrophage- and Î ³ δT cell-mediated response against Mycobacterium tuberculosis. Blood Cancer Journal, 2018, 8, 100.	6.2	31
5	Chronic Lymphocytic Leukemia Cells Bind and Present the Erythrocyte Protein Band 3: Possible Role as Initiators of Autoimmune Hemolytic Anemia. Journal of Immunology, 2008, 181, 3674-3683.	0.8	30
6	The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells. Investigational New Drugs, 2012, 30, 1830-1840.	2.6	26
7	The Expression of Sphingosine-1 Phosphate Receptor-1 in Chronic Lymphocytic Leukemia Cells Is Impaired by Tumor Microenvironmental Signals and Enhanced by Piceatannol and R406. Journal of Immunology, 2014, 193, 3165-3174.	0.8	21
8	CXCL12 is a costimulator for CD4+ T cell activation and proliferation in chronic lymphocytic leukemia patients. Cancer Immunology, Immunotherapy, 2013, 62, 113-124.	4.2	17
9	Methylation status regulates lipoprotein lipase expression in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2013, 54, 1844-1848.	1.3	16
10	The effect of ibrutinib on neutrophil and γδT cell functions. Leukemia and Lymphoma, 2020, 61, 2409-2418.	1.3	16
11	SHIP-1 protein level and phosphorylation status differs between CLL cells segregated by ZAP-70 expression. British Journal of Haematology, 2007, 140, 071116225528001-???.	2.5	15
12	Lipoprotein lipase expression in unmutated CLL patients is the consequence of a demethylation process induced by the microenvironment. Leukemia, 2013, 27, 721-725.	7.2	15
13	Chronic lymphocytic leukemia cells increase neutrophils survival and promote their differentiation into CD16 ^{high} CD62L ^{dim} immunosuppressive subset. International Journal of Cancer, 2019, 144, 1128-1134.	5.1	15
14	The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients. Cancer Immunology, Immunotherapy, 2017, 66, 461-473.	4.2	14
15	Autologous T-cell activation fosters ABT-199 resistance in chronic lymphocytic leukemia: rationale for a combined therapy with SYK inhibitors and anti-CD20 monoclonal antibodies. Haematologica, 2018, 103, e458-e461.	3.5	14
16	Decidualization Process Induces Maternal Monocytes to Tolerogenic IL-10-Producing Dendritic Cells (DC-10). Frontiers in Immunology, 2020, 11, 1571.	4.8	14
17	CXCL12-induced chemotaxis is impaired in T cells from patients with ZAP-70-negative chronic lymphocytic leukemia. Haematologica, 2010, 95, 768-775.	3.5	13
18	Revisiting the role of interleukin-8 in chronic lymphocytic leukemia. Scientific Reports, 2017, 7, 15714.	3.3	13

Mercedes Borge

#	Article	IF	CITATIONS
19	In Vitro Sensitivity to Venetoclax and Microenvironment Protection in Hairy Cell Leukemia. Frontiers in Oncology, 2021, 11, 598319.	2.8	13
20	Second generation <scp>BTK</scp> inhibitors impair the antiâ€fungal response of macrophages and neutrophils. American Journal of Hematology, 2020, 95, E174-E178.	4.1	10
21	Sphingosine kinase 1 participates in the activation, proliferation and survival of chronic lymphocytic leukemia cells. Haematologica, 2017, 102, e257-e260.	3.5	9
22	Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype. Cancer Immunology, Immunotherapy, 2022, 71, 979-987.	4.2	7
23	CCR4 expression in a case of cutaneous Richter's transformation of chronic lymphocytic leukemia (CLL) to diffuse large B-cell lymphoma (DLBCL) and in CLL patients with no skin manifestations. European Journal of Haematology, 2011, 87, 80-86.	2.2	6
24	Soluble RANKL production by leukemic cells in a case of chronic lymphocytic leukemia with bone destruction. Leukemia and Lymphoma, 2016, 57, 2468-2471.	1.3	6
25	Immunoregulatory effects of Lurbinectedin in chronic lymphocytic leukemia. Cancer Immunology, Immunotherapy, 2020, 69, 813-824.	4.2	6
26	Surface localization of high-mobility group nucleosome-binding protein 2 on leukemic B cells from patients with chronic lymphocytic leukemia is related to secondary autoimmune hemolytic anemia. Leukemia and Lymphoma, 2015, 56, 1115-1122.	1.3	5
27	Immunomodulatory effects of different intravenous immunoglobulin preparations in chronic lymphocytic leukemia. Scientific Reports, 2021, 11, 12926.	3.3	3
28	Expression and function of cathelicidin hCAP18/LL-37 in chronic lymphocytic leukemia. Haematologica, 2020, 105, e465-469.	3.5	3
29	Somatic Hypermutation Defects in Common Variable Immune Deficiency. Current Allergy and Asthma Reports, 2017, 17, 76.	5.3	1
30	2.8 CXCL12 Is a Costimulator for CD4+ T-Cell Activation and Proliferation in Patients with Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S164.	0.4	0
31	Human Monocytes and Monocyte-Like Cells Are Highly Sensitive to Plitidepsin-Induced Cell Death In In Vitro Assays. Blood, 2010, 116, 4942-4942.	1.4	0
32	Sphingosine Kinases (SK): Key Molecules Associated with the Activation, Proliferation and Ibrutinib-Induced Cell Death of Chronic Lympocytic Leukemia Cells. Blood, 2015, 126, 1714-1714.	1.4	0